Mizuho Securities analyst Steven Valiquette has maintained their neutral stance on GDRX stock, giving a Hold rating on February 28.
Steven Valiquette’s rating is based on several key observations from GoodRx Holdings’ recent performance and future outlook. The company’s market share in the prescription discount segment showed growth, and the new CEO has identified a stronger value proposition for retail pharmacies than previously anticipated. This is expected to enhance future contracting opportunities with retailers. Additionally, the Manufacturer Solutions segment is projected to be a significant growth driver, with an expected 20% growth in 2025 due to an increase in contracted brands.
Despite these positive indicators, the company’s earnings per share estimates for 2025 and 2026 remain unchanged, reflecting results that align with market expectations. The revenue and EBITDA guidance for 2025 also matched the Street’s consensus, indicating stable but not exceptional performance. Furthermore, the potential risk associated with retail pharmacy store closures over the next few years has led to a cautious approach, maintaining a $5 price target and a Hold rating. This balanced view reflects both the opportunities and challenges facing GoodRx Holdings.
In another report released on February 28, Morgan Stanley also maintained a Hold rating on the stock with a $6.00 price target.
GDRX’s price has also changed moderately for the past six months – from $7.860 to $4.850, which is a -38.30% drop .